Mylan (MYL) is dealing with more negative reports on executive pay. The company, which has come under fire for the price of the life-saving EpiPen, has the second-highest executive compensation package in the industry, according to the Wall Street Journal. Over the past five years, Mylan has paid its top five managers a total of nearly $300 million. That figure is surprising because Mylan isn't that large of a company. The drug maker ranks 11 in the U.S. by revenue and 16 by market cap.
More from Video
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.
AMSC CEO discusses that and China challenges.